Speaker

Matthew Farren

Senior Research, Pharmacology Investigator, Incyte Corporation

Matthew Farren, Senior Research, Pharmacology Investigator at Incyte Corporation, spoke at 8th RAS-Targeted Drug Development Summit (Boston, United States of America, 8–10 Sept 2026) in the session “Expanding Patient Reach: Developing Novel INCB161734 (KRAS G12D Inhibitors) Combinations That Work Across Heterogeneous Tumors”.

Conferences: 1
Keynotes: 0
Upcoming: 0

Pharmacy & Pharmaceutical Sciences

Past appearances

8th RAS-Targeted Drug Development Summit
8–10 Sept 2026Boston, United States of America
- SpeakerExpanding Patient Reach: Developing Novel INCB161734 (KRAS G12D Inhibitors) Combinations That Work Across Heterogeneous Tumors
- PanelPanel Discussion: How Do We Build Combination Strategies That Work Across KRAS Alleles, Co Mutations, & Tumor Types?With Andrea Wang Gillam, Silvia Coma, Zhan Yao

More speakers at 8th RAS-Targeted Drug Development Summit

Luke Pase
Chief Technology Officer, Anocca AB
Nagi Ayad
Professor, Georgetown University
Stephanie Braun
Executive Director & Head of Enzalutamide, Medical Affairs (US), Astellas Pharma
Peter DeMuth
Chief Scientific Officer, Elicio Therapeutics
George Fromm
Chief Scientific Officer, KAYAK
Michael Hamilton
Scientist II, Vividion Therapeutics

See all 29 speakers on the event page

This profile is built from conference programmes published on kongre.net. It has not been claimed or confirmed by Matthew Farren, and it lists only the talks, sessions and presentations named in those programmes.

Is this you? Claim this profile — every request is read by a person before anything is linked.

To ask for a correction or for this profile to be removed, email [email protected].